LSD-1 ENZYME INHIBITORS FOR INDUCING OSTEOGENIC DIFFERENTIATION

• US 20130109751A1
• Filed: 10/24/2012
• Published: 05/02/2013
• Est. Priority Date: 10/28/2011
• Status: Abandoned Application

• Current Assignee: Mesogenics S.r.l.
• Original Assignee: Mesogenics S.r.l.
• Inventors: SALVATORE, Francesco
• Application Number:
  US13/659,167
• Publication Number:
  US 20130109751A1
• Time in Patent Office: Days
• US Class Current: 514/485
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/27 of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis

Abstract

The present invention relates to the use of LSD-1 enzyme inhibitors in the osteogenic differentiation of cells capable to differentiate into osteoblasts, especially mesenchymal stem cells, adult stem cells, and cells with osteogenic potential

Claims

1. LSD-1 enzyme inhibitors for use in the osteogenic differentiation of cells capable of differentiating into osteoblasts and/or in the maintenance of bone maturation.

2. Inhibitors for use according to claim 1, wherein the cells are mesenchymal stem cells.

3. Inhibitors for use according to claim 1, wherein the cells are adult stem cells.

4. Inhibitors for use according to claim 1, wherein the cells are cells with osteogenic potential.

5. Inhibitors for use according to claims 1-4, wherein the inhibitor is tranylcypromine.

6. Inhibitors for use according to claims 1-4, wherein the inhibitor is the compound MC2580 of formula (I):

7. Inhibitors for use according to claims 1-6, in the surgical and/or orthopaedic field.

8. Inhibitors for use according to claims 1-7, in the treatment of bone diseases due to a reduction of the bone neo-synthesis or to the increase of the bone resorption.

9. Inhibitors for use according to claim 8, wherein the bone diseases are osteoporosis, osteomalacia and discontinuous bone fractures.

10. Inhibitors for use according to claims 1-7, in arthrodesis and/or medical devices for use in bone synthesis induction for fracture repair.

11. Inhibitors for use according to claims 1-6, in the preparation of culture media and/or serum substitutes and/or any additive for the cell culture.

12. Pharmaceutical composition comprising an LSD-1 enzyme inhibitor for use in the osteogenic differentiation of cells capable of differentiating into osteoblasts and/or in the maintenance of bone maturation and a pharmaceutically acceptable adjuvant or carrier.